Rett Syndrome Gene Therapy Data Will Be Presented
Researchers will showcase ongoing clinical trial results for a potential gene-transfer treatment in October 2026.
Updated on Oct. 1, 2026 in Autism
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparent updates on clinical trial progress?
Taysha Gene Therapies is scheduled to present encore data from its clinical program for TSHA-102, an investigational gene therapy for Rett syndrome, at the 55th Child Neurology Society Annual Meeting in Montréal. These findings will be shared between October 14 and October 17, 2026.
Why it matters
Because there are currently no approved disease-modifying therapies for Rett syndrome, these presentations offer an update on research that may eventually change the standard of care. This investigational approach aims to address the condition for the estimated 15,000 to 20,000 affected patients in the U.S., EU, and U.K.
The encore presentations highlight data previously shared at the 2026 International Rett Syndrome Foundation Scientific Meeting. Researchers will share results from the REVEAL Phase 1/2 trial of TSHA-102, which remains under clinical investigation.
The players
Taysha Gene Therapies
A biotechnology company focused on developing gene therapies for severe and rare monogenic central nervous system diseases.
Child Neurology Society
An association of pediatric neurologists that facilitates professional exchange and research dissemination.
The details
TSHA-102 is an investigational AAV9 gene transfer therapy designed to deliver a functional form of the MECP2 gene to cells within the central nervous system. The treatment utilizes miRNA-Responsive Auto-Regulatory Element technology to regulate MECP2 expression levels, aiming to restore proper function in the affected biological pathways.
Timeline
October 14-17, 2026: The 55th Child Neurology Society Annual Meeting takes place in Montréal.
October 15, 2026: Oral and poster presentations on the REVEAL Phase 1/2 trial are scheduled.
October 16, 2026: A company-hosted symposium regarding the therapy will be held.
Health Landscape
The development of TSHA-102 represents a significant effort to introduce the first disease-modifying therapy for Rett syndrome. It follows a pattern of emerging gene-transfer technologies currently being evaluated in clinical pipelines for rare genetic neurodevelopmental conditions.
These presentations represent ongoing clinical research rather than an available clinical treatment. Patients and families interested in the potential of gene-based interventions should speak with their neurologist about current clinical trial opportunities and emerging therapeutic research.
The takeaway
While gene therapy research continues to advance, currently there are no disease-modifying treatments approved for Rett syndrome. Families are encouraged to discuss the implications of upcoming clinical trial results with their primary medical specialists.
Further reading
For broader context on neurodevelopmental conditions and related research, visit our Autism section.
Live Poll
Do you trust that pharmaceutical companies provide sufficient transparent updates on clinical trial progress?
